Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors.
Proceedings of the National Academy of Sciences, Volume 104, No. 24, June 12, 2007.
NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality
European Journal of Cancer, Volume 48, No. 12, 2012.
Delayed response and survival from NovoTTF-100A in recurrent GBM.
Medical Oncology, Volume 3, No. 338, January 2013.
Response assessment of NovoTTF-100A vs best physician’s choice of chemotherapy in recurrent glioblastoma.
Cancer Medicine, Volume 3, No. 3, 2014.
Characterization and management of dermatologic adverse events with the NovoTTF-100A system, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma.
Seminars in Oncology, Volume 41, S1 – S14, June, 2014.
Post hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A™ system versus best physician’s choice chemotherapy.
Seminars in Oncology, Volume 41, S25 – S34, October, 2014.
Response patterns of recurrent glioblastomas treated With Tumor Treating Fields.
Seminars in Oncology, Volume 41, S14 – S24, October, 2014.
Clinical practice experience with NovoTTF-100A™ system for glioblastoma: the Patient Registry Dataset (PRiDe).
Seminars in Oncology, Volume 41, S4 – S13, October, 2014.
